Neurocrine Biosciences, Inc. (LON:0K6R)
141.50
-2.54 (-1.76%)
Dec 30, 2025, 5:00 PM BST
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $794.90M USD in the quarter ending September 30, 2025, with 27.78% growth. This brings the company's revenue in the last twelve months to $2.68B, up 19.61% year-over-year. In the year 2024, Neurocrine Biosciences had annual revenue of $2.36B with 24.81% growth.
Revenue (ttm)
$2.68B
Revenue Growth
+19.61%
P/S Ratio
5.23
Revenue / Employee
$1.49M
Employees
1,800
Market Cap
10.43B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.36B | 468.20M | 24.81% |
| Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
| Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
| Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
| Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
| Dec 31, 2019 | 788.10M | 336.90M | 74.67% |
| Dec 31, 2018 | 451.20M | 289.57M | 179.16% |
| Dec 31, 2017 | 161.63M | 146.63M | 977.51% |
| Dec 31, 2016 | 15.00M | -4.77M | -24.12% |
| Dec 31, 2015 | 19.77M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 2.92M | -50.22M | -94.51% |
| Dec 31, 2012 | 53.14M | -24.27M | -31.36% |
| Dec 31, 2011 | 77.41M | 43.91M | 131.08% |
| Dec 31, 2010 | 33.50M | 30.55M | 1,034.47% |
| Dec 31, 2009 | 2.95M | -1.02M | -25.71% |
| Dec 31, 2008 | 3.98M | 2.75M | 224.75% |
| Dec 31, 2007 | 1.22M | -38.01M | -96.88% |
| Dec 31, 2006 | 39.23M | -84.66M | -68.33% |
| Dec 31, 2005 | 123.89M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Neurocrine Biosciences News
- 7 days ago - Clinical Miss For Neurocrine's Cerebral Palsy Drug, But Analysts See Limited Damage - Benzinga
- 7 days ago - Clinical Miss For Neurocrine's Cerebral Palsy Drug, But Analysts See Limited Damage - Benzinga
- 7 days ago - Neurocrine : Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal - Nasdaq
- 8 days ago - Neurocrine Biosciences (NBIX) Faces Setback with Ingrezza Trial - GuruFocus
- 8 days ago - Neurocrine's movement disorder treatment fails late-stage trial - Reuters
- 8 days ago - Neurocrine Biosciences (NBIX) Phase 3 Trial Results Disappoint in DCP Treatment - GuruFocus
- 8 days ago - Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy - PRNewsWire
- 13 days ago - NBIX: HC Wainwright & Co. Raises Price Target to $198, Maintains Buy Rating | NBIX Stock News - GuruFocus